Abstract
Background:
Novel therapeutic agents are currently being investigated for neuroendocrine tumour treatment.
Case presentation:
We report here on the case of a patient presenting with hypersensitivity pneumonitis while being treated with everolimus, a mammalian target of rapamycin (mTOR) inhibitor.
Conclusion:
Side effects of everolimus should be familiar to clinicians, including nonspecialists, and be monitored carefully to allow for prompt management.
MeSH terms
-
Alveolitis, Extrinsic Allergic / chemically induced*
-
Alveolitis, Extrinsic Allergic / pathology
-
Antineoplastic Agents / adverse effects*
-
Everolimus
-
Humans
-
Intestine, Small / drug effects
-
Intestine, Small / pathology
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / secondary
-
Male
-
Middle Aged
-
Neuroendocrine Tumors / drug therapy*
-
Neuroendocrine Tumors / pathology
-
Sirolimus / adverse effects
-
Sirolimus / analogs & derivatives*
Substances
-
Antineoplastic Agents
-
Everolimus
-
Sirolimus